Cue Biopharma, Inc.

CUE · Nasdaq · SIC 2834: Pharmaceutical Preparations
147
SEC Filings

Business Summary

PART I Overview We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. Unlike conventional approaches that broadly activate the immune system, our Immuno-STAT platform is designed to selectively modulate disease-relevant T cells, enhancing efficacy while minimizing off-target effects. We believe our Immuno-STAT platform h...

Next Earnings

Q2 FY2026 — expected 2026-09-20

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCUEdiscussed_in_filing Cybersecurity
topic_mentionCUEdiscussed_in_filing Cybersecurity
topic_mentionCUEdiscussed_in_filing Healthcare & Bio
topic_mentionCUEdiscussed_in_filing Platform & Ecosystem
topic_mentionCUEdiscussed_in_filing Healthcare & Bio
topic_mentionCUEdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-162025-12-310001193125-26-108287EDGAR106K words
2025-03-312024-12-310000950170-25-047677EDGAR—
2024-03-282023-12-310000950170-24-038059EDGAR—
2023-03-212022-12-310000950170-23-008927EDGAR—
2022-03-162021-12-310000950170-22-003969EDGAR—
2021-03-092020-12-310001564590-21-011777EDGAR—
2020-03-122019-12-310001564590-20-010212EDGAR—
2019-03-142018-12-310001564590-19-007832EDGAR—
2018-03-292017-12-310001144204-18-017978EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001193125-25-277466EDGAR30K words
2025-08-122025-06-300000950170-25-107270EDGAR—
2025-05-122025-03-310000950170-25-069125EDGAR—
2024-11-142024-09-300000950170-24-127005EDGAR—
2024-08-142024-06-300000950170-24-096967EDGAR—
2024-05-092024-03-310000950170-24-056838EDGAR—
2023-11-032023-09-300000950170-23-058838EDGAR—
2023-08-082023-06-300000950170-23-039770EDGAR—
2023-05-092023-03-310000950170-23-019646EDGAR—
2022-11-142022-09-300000950170-22-024991EDGAR—
2022-08-042022-06-300000950170-22-014747EDGAR—
2022-05-102022-03-310000950170-22-008990EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-270001193125-26-128993EDGAR2K words
2026-03-160001193125-26-108292EDGAR—
2026-02-180001193125-26-056983EDGAR—
2026-02-120001193125-26-047717EDGAR—
2025-12-190001193125-25-326925EDGAR—
2025-11-240001193125-25-292093EDGAR—
2025-11-200001193125-25-289713EDGAR—
2025-11-120001193125-25-277468EDGAR—
2025-11-060001193125-25-268135EDGAR—
2025-09-290000950130-25-000140EDGAR—

147 total filings indexed. 116 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001645460
TickerCUE
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: f7fefef2c54ac1b8cb8db2b1bf179ac4e85407c74d227ec562c315331fb85581
parent: 1ada3dd974a9bd28dba4be34187d704eb2da259417720ec8405aaf636d1d47b1
content hash: 177c6e697e4760ed93aa8de09c953c55a5786359bf191b7ad64a6338e7538d01
signed: 2026-04-13T04:44:33.273Z
sources: 21 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf